Regeneron Pharmaceuticals Inc
REGN557.910USD
-13.149-2.30%
收盤 04/15, 16:00（美東）報價延遲15分鐘
61.15B總市值
13.86本益比TTM
關於 Regeneron Pharmaceuticals Inc 公司
Regeneron Pharmaceuticals, Inc. 是一家綜合性生物技術公司。該公司發明、開發、製造和銷售用於治療嚴重疾病的藥物。其產品和正在開發的產品候選物旨在幫助患有眼部疾病、過敏和炎症性疾病、癌症、心血管和代謝疾病、神經系統疾病、血液病、傳染病和罕見疾病的患者。該公司通過其 VelociSuite 技術（例如 VelocImmune，它使用基因人源化小鼠生產優化的全人抗體和雙特異性抗體）以及通過 Regeneron Genetics Center 等雄心勃勃的研究計劃，幫助加速和改進傳統的藥物開發流程。其上市產品包括 EYLEA（阿柏西普）注射液；Dupixent（dupilumab）注射液；Libtayo（cemiplimab）注射液；Praluent（alirocumab）注射液；Kevzara（sarilumab）注射液等。
公司簡介
公司代碼REGN
公司名稱Regeneron Pharmaceuticals Inc
上市日期Apr 02, 1991
成立日期1988
CEODr. Leonard S. Schleifer, M.D., Ph.D
員工數量15106
證券類型Ordinary Share
年結日Apr 02
公司地址777 Old Saw Mill River Road
城市TARRYTOWN
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編10591
電話17813705000
網址https://www.regeneron.com/
公司代碼REGN
上市日期Apr 02, 1991
成立日期1988
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
782.24K
-11.33%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
695.45K
--
Dr. Neil Stahl, Ph.D.
Dr. Neil Stahl, Ph.D.
Executive Vice President - Research and Development
Executive Vice President - Research and Development
54.50K
-1.39%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
53.40K
+3.80%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
42.00K
+2.78%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
35.89K
+6.02%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
29.90K
+0.56%
Mr. Arthur F. (Art) Ryan
Mr. Arthur F. (Art) Ryan
Independent Director
Independent Director
17.67K
+0.95%
Mr. Christopher R. Fenimore
Mr. Christopher R. Fenimore
Chief Financial Officer, Senior Vice President - Finance
Chief Financial Officer, Senior Vice President - Finance
16.35K
+6.24%
Ms. Marion E. McCourt
Ms. Marion E. McCourt
Executive Vice President - Commercial
Executive Vice President - Commercial
14.37K
+9.94%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
782.24K
-11.33%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
695.45K
--
Dr. Neil Stahl, Ph.D.
Dr. Neil Stahl, Ph.D.
Executive Vice President - Research and Development
Executive Vice President - Research and Development
54.50K
-1.39%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
53.40K
+3.80%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
42.00K
+2.78%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
35.89K
+6.02%
收入明細
單位: USD更新時間: 4月6日 週日
單位: USD更新時間: 4月6日 週日
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
EYLEA
4.77B
33.57%
Sanofi
4.53B
31.91%
Bayer
1.50B
10.55%
EYLEA HD
1.20B
8.46%
Libtayo
787.30M
5.54%
Other
1.42B
9.97%
暫無數據
業務
地區
業務USD
名稱
營收
佔比
EYLEA
4.77B
33.57%
Sanofi
4.53B
31.91%
Bayer
1.50B
10.55%
EYLEA HD
1.20B
8.46%
Libtayo
787.30M
5.54%
Other
1.42B
9.97%
股東統計
更新時間: 2月21日 週五
更新時間: 2月21日 週五
持股股東
股東類型
持股股東
股東統計
佔比
The Vanguard Group, Inc.
8.59%
Fidelity Management & Research Company LLC
7.41%
BlackRock Institutional Trust Company, N.A.
5.30%
JP Morgan Asset Management
4.88%
State Street Global Advisors (US)
4.49%
Other
69.32%
持股股東
股東統計
佔比
The Vanguard Group, Inc.
8.59%
Fidelity Management & Research Company LLC
7.41%
BlackRock Institutional Trust Company, N.A.
5.30%
JP Morgan Asset Management
4.88%
State Street Global Advisors (US)
4.49%
Other
69.32%
股東類型
股東統計
佔比
Investment Advisor
47.88%
Investment Advisor/Hedge Fund
33.06%
Research Firm
2.77%
Pension Fund
2.59%
Bank and Trust
2.16%
Hedge Fund
2.07%
Individual Investor
1.66%
Sovereign Wealth Fund
1.15%
Insurance Company
0.08%
Other
6.57%
機構持股
更新時間: 1月19日 週日
更新時間: 1月19日 週日
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
2516
100.27M
93.27%
-268.91K
2024Q4
2581
100.17M
93.15%
-475.65K
2024Q3
2505
99.81M
90.67%
-1.99M
2024Q2
2479
100.87M
93.10%
+570.24K
2024Q1
2440
99.77M
92.44%
+388.23K
2023Q4
2406
98.50M
91.94%
-617.06K
2023Q3
2358
98.79M
92.52%
-1.71M
2023Q2
2360
99.25M
92.00%
-1.42M
2023Q1
2366
99.66M
92.70%
-1.10M
2022Q4
2333
99.78M
93.16%
-1.62M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
9.24M
8.59%
-32.55K
-0.35%
Dec 31, 2024
Fidelity Management & Research Company LLC
7.97M
7.41%
-2.08M
-20.68%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
5.70M
5.3%
+193.71K
+3.52%
Dec 31, 2024
JP Morgan Asset Management
5.24M
4.88%
-524.97K
-9.10%
Dec 31, 2024
State Street Global Advisors (US)
4.83M
4.49%
-70.17K
-1.43%
Dec 31, 2024
Capital International Investors
4.74M
4.41%
+1.39M
+41.55%
Dec 31, 2024
Capital World Investors
2.78M
2.58%
-1.52M
-35.35%
Dec 31, 2024
Geode Capital Management, L.L.C.
2.43M
2.26%
+155.37K
+6.84%
Dec 31, 2024
Dodge & Cox
2.32M
2.16%
+9.38K
+0.41%
Dec 31, 2024
Invesco Capital Management (QQQ Trust)
2.24M
2.08%
+29.93K
+1.36%
Feb 28, 2025
查看更多
持股ETF
更新時間: 4月6日 週日
更新時間: 4月6日 週日
機構名稱
佔比
Tema Neuroscience and Mental Health ETF
7.56%
Invesco Nasdaq Biotechnology ETF
7.22%
ProShares Ultra Nasdaq Biotechnology
6.8%
Simplify Health Care ETF
6.73%
iShares Biotechnology ETF
6.22%
VanEck Biotech ETF
4.94%
Invesco Biotechnology & Genome ETF
4.65%
iShares Genomics Immunology and Healthcare ETF
4%
Franklin Genomic Advancements ETF
3.51%
Invesco QQQ Low Volatility ETF
3.35%
查看更多
Tema Neuroscience and Mental Health ETF
佔比7.56%
Invesco Nasdaq Biotechnology ETF
佔比7.22%
ProShares Ultra Nasdaq Biotechnology
佔比6.8%
Simplify Health Care ETF
佔比6.73%
iShares Biotechnology ETF
佔比6.22%
VanEck Biotech ETF
佔比4.94%
Invesco Biotechnology & Genome ETF
佔比4.65%
iShares Genomics Immunology and Healthcare ETF
佔比4%
Franklin Genomic Advancements ETF
佔比3.51%
Invesco QQQ Low Volatility ETF
佔比3.35%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
Feb 04, 2025
REGN.NB Interim Cash Dividend of gross USD 0.88 paid on Mar 20, 2025 going ex on Feb 20, 2025
Feb 20, 2025
Mar 20, 2025
Feb 20, 2025
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據